Halozyme Therapeutics (HALO) Projected to Announce Earnings on Thursday

04 Aug 2026, 06:10 by Michael Walen · The Markets Daily

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) is expected to be releasing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of $1.79 per share and revenue of $402.28 million for the quarter. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Parties can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last released its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.06. The firm had revenue of $376.71 million for the quarter, compared to the consensus estimate of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The firm’s revenue was up 42.2% on a year-over-year basis. During the same period in the prior year, the firm earned $1.11 EPS. On average, analysts expect Halozyme Therapeutics to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $82.27 on Tuesday. The firm has a market capitalization of $9.76 billion, a price-to-earnings ratio of 29.59, a price-to-earnings-growth ratio of 0.34 and a beta of 0.85. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33. The business has a fifty day moving average of $74.80 and a 200 day moving average of $70.99. Halozyme Therapeutics has a 1 year low of $58.67 and a 1 year high of $84.44.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. UBS Group reissued a “buy” rating and issued a $90.00 price objective on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. HC Wainwright reaffirmed a “buy” rating and set a $95.00 target price on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday. Finally, Wall Street Zen raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. Eight analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $81.60.

View Our Latest Stock Analysis on Halozyme Therapeutics

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Mahesh Krishnan sold 7,304 shares of Halozyme Therapeutics stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the transaction, the director owned 14,462 shares in the company, valued at approximately $1,084,650. This trade represents a 33.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the business’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $76.71, for a total value of $124,653.75. Following the completion of the transaction, the director directly owned 42,044 shares of the company’s stock, valued at approximately $3,225,195.24. This trade represents a 3.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 72,477 shares of company stock valued at $5,102,643. Company insiders own 2.50% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of HALO. Larson Financial Group LLC grew its stake in shares of Halozyme Therapeutics by 3,118.2% during the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 343 shares during the period. Wexford Capital LP purchased a new position in shares of Halozyme Therapeutics during the 3rd quarter valued at approximately $70,000. Employees Retirement System of Texas lifted its stake in shares of Halozyme Therapeutics by 64.6% in the 3rd quarter. Employees Retirement System of Texas now owns 1,088 shares of the biopharmaceutical company’s stock valued at $80,000 after purchasing an additional 427 shares during the period. UMB Bank n.a. lifted its stake in shares of Halozyme Therapeutics by 18.2% in the 4th quarter. UMB Bank n.a. now owns 1,296 shares of the biopharmaceutical company’s stock valued at $87,000 after purchasing an additional 200 shares during the period. Finally, Smartleaf Asset Management LLC boosted its holdings in Halozyme Therapeutics by 21.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,399 shares of the biopharmaceutical company’s stock worth $95,000 after buying an additional 251 shares in the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

About Halozyme Therapeutics

(Get Free Report)

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.